Ieq Capital LLC Acquires 9,874 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Ieq Capital LLC boosted its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 86.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,241 shares of the company’s stock after purchasing an additional 9,874 shares during the quarter. Ieq Capital LLC’s holdings in Takeda Pharmaceutical were worth $281,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of TAK. FMR LLC raised its position in shares of Takeda Pharmaceutical by 10.9% during the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock valued at $41,365,000 after buying an additional 286,052 shares in the last quarter. Stifel Financial Corp raised its position in Takeda Pharmaceutical by 103.9% during the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock valued at $6,266,000 after purchasing an additional 224,594 shares during the period. Summit Global Investments raised its position in Takeda Pharmaceutical by 86.0% during the third quarter. Summit Global Investments now owns 415,558 shares of the company’s stock valued at $5,909,000 after purchasing an additional 192,143 shares during the period. Crossmark Global Holdings Inc. lifted its stake in shares of Takeda Pharmaceutical by 284.9% in the 4th quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock valued at $2,787,000 after purchasing an additional 155,795 shares during the last quarter. Finally, Van ECK Associates Corp boosted its holdings in shares of Takeda Pharmaceutical by 6.6% in the 3rd quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock worth $30,149,000 after purchasing an additional 134,407 shares during the period. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Performance

NYSE:TAK opened at $14.40 on Friday. The firm has a market capitalization of $45.82 billion, a PE ratio of 36.00, a PEG ratio of 0.24 and a beta of 0.51. The stock’s fifty day moving average is $13.41 and its 200 day moving average is $13.89. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.57 and a fifty-two week high of $15.08. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.